Another protein degradation biotech emerges, with the promise of a new approach from an old hand
The money keeps pouring in for protein degradation.
A field that six years ago had the financial equivalent of tumbleweed is now flush with cash. Last month, a pair of biotechs, now backed with big pharma and big biotech deals, landed a total of $222 million in funding on consecutive days. And in October, Plexium launched out of San Diego with $28 million in Series A financing and a promise for a different approach to a barely adult field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.